Navigation Links
Transdel Pharmaceuticals Enters Into License Agreement with JH Direct, LLC for Cosmeceutical Product

Agreement Includes Exclusive Worldwide License to Transdel's Anti-Cellulite Cosmeceutical Product

LA JOLLA, Calif., June 10 /PRNewswire-FirstCall/ -- Transdel Pharmaceuticals, Inc. (OTC Bulletin Board: TDLP) and JH Direct, LLC have entered into a licensing agreement providing JH Direct with the exclusive worldwide rights to Transdel's anti-cellulite cosmeceutical product which utilizes Transdel's patented transdermal delivery system technology, Transdel(TM). The licensing agreement between Transdel and JH Direct is a significant milestone for Transdel as it is the first agreement involving the use of Transdel's proprietary technology for a cosmeceutical product. Transdel plans to further develop its pipeline of cosmetic/cosmeceutical products.

Under the terms of the agreement, JH Direct will pay Transdel initial royalty advances and a continuing licensing royalty on the worldwide sales of the anti-cellulite product. The product will be launched through direct response television campaigns, created and managed by JH Direct, followed by an expansion into traditional channels of distribution, such as retail or wholesale channels. Transdel has retained the exclusive rights to seek pharmaceutical/dermatological partners for the anti-cellulite product for an initial period of one year, thereafter JH Direct will be allowed to expand in this channel.

"We are extremely pleased with our relationship with JH Direct and plan on building on this relationship to launch additional cosmeceutical products. This venture is very exciting as we believe it could represent the beginning of what may become a revenue stream for Transdel. An estimated 85% to 90% of women develop cellulite following puberty. The size of this target market combined with the desire to remove cellulite represents a $3 billion market and thus provides a promising market opportunity," stated Dr. Juliet Singh, President and Chief Executive Officer of Transdel. "We also plan on expanding our pipeline to include formulations for anti-aging, varicose vein and hyperpigmentation cosmetic/cosmeceutical products."

"We feel that the anti-cellulite product provides a significant market opportunity for JH Direct. The use of Transdel's propriety transdermal delivery system in the product will make it unique and potentially more effective than other products currently on the market," said Johann Verheem, JH Direct's Chief Executive Officer. "We anticipate bringing this product to market rapidly and expanding our relationship with Transdel in other areas."

About Transdel Pharmaceuticals, Inc.

Transdel Pharmaceuticals, Inc. (OTCBB: TDLP) is a specialty pharmaceutical company developing non-invasive, topically delivered products. The Company's innovative-patented Transdel(TM) cream formulation technology is designed to facilitate the effective penetration of a variety of products through the tough skin barrier. The Company is actively investigating other product candidates for transdermal delivery using the Transdel(TM) platform technology and is also actively pursuing partnerships with other groups or companies to expand its product portfolio.

The Company's lead pain product, Ketotransdel(R), a topical cream based non-steroidal anti-inflammatory drug ("NSAID"), is currently in Phase 3 clinical studies in the United States. Ketotransdel, if approved by the U.S. Food and Drug Administration, could become the first topical NSAID cream product in the United States for acute pain management, which is a multi-billion dollar market. The drug could address what the Company believes is a significant unmet medical need for patients and physicians seeking a potentially safer alternative to existing pain management approaches, such as oral NSAIDs. The Company anticipates reporting top-line results from this study during the third quarter of 2009. For more information, please visit

About JH Direct, LLC

JH Direct LLC is a fully integrated Direct Response Television Company focusing on developing sustainable brands launched through direct response television campaigns as part of a multi-channel distribution approach. The JH Direct senior management team has created and managed some of the most successful Direct Response Television brands in the cosmeceutical, beauty and fitness categories since the mid nineties.

JH Direct is funded by JH Partners, a San Francisco-based private equity firm focused on building sustainable, long-term equity value in consumer and marketing-driven growth companies.

Safe Harbor Statement

Statements made in this release that are not historical in nature constitute forward-looking statements. Forward-looking statements can be identified by the use of words such as "expects," "plans," "will," "may," "anticipates," "believes," "should," "intends," "estimates," and other words of similar meaning. Please note that forward-looking statements are based on projections, that these projections involve judgment, and that individual judgments may vary. Moreover, these statements are subject to risks and uncertainties that cannot be predicted or quantified and consequently, actual results may differ materially from those expressed or implied by such forward-looking statements. Such risks and uncertainties include, without limitation, risks and uncertainties associated with the uncertainty of the Company's future financial results and its ability to raise additional funds to support its operations, its ability to complete the required clinical trials and obtain FDA approval for Ketotransdel, the efficacy and the commercial success of any cosmetic/cosmeceutical products it develops, the impact of competitive products or pricing, and technological changes. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company's filings with the Securities and Exchange Commission, including its Annual Report on Form 10-K and its Quarterly Reports on Form 10-Q filed with the SEC. Such documents may be read free of charge on the SEC's web site at All forward-looking statements included in this release are made as of the date of this press release, and the Company assumes no obligation to update any such forward-looking statements.

SOURCE Transdel Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Transdel Pharmaceuticals, Inc. Featured on National Broadcast Television
2. Transdel Pharmaceuticals, Inc. Retains FLP Pharma to Lead Business Development Activities
3. Transdel Expands Program to Include Cosmetic/Cosmeceutical Products
4. Transdel Pharmaceuticals Appoints Mr. Lynn Swann, Pro-Football Hall of Famer, ABC Sports Broadcaster, and Former Chairman of the Presidents Council on Physical Fitness and Sports, to Board of Directors
5. Transdel Pharmaceuticals to Present at Cowen and Companys 28th Annual Health Care Conference
6. Jazz Pharmaceuticals to Present Data From First Phase III Study of Sodium Oxybate in Patients With Fibromyalgia
7. Quark Pharmaceuticals Announces the Presentation of Data Indicating Potential Utility of QPI-1002 in Chronic Kidney Disease at the RNA Interference Summit
8. Keryx Biopharmaceuticals, Inc. Receives Extension for Nasdaq Listing Compliance
9. Raptor Pharmaceuticals to Collaborate with Roche on Therapeutic Delivery Across Blood-Brain Barrier
10. Metastorm Customer, Wyeth Pharmaceuticals, Wins CIO 100 Award for BPM Project
11. Endo Pharmaceuticals to Present at Goldman Sachs 30th Annual Healthcare Conference
Post Your Comments:
(Date:11/24/2015)... ALEXANDRIA, VA (PRWEB) , ... November 24, 2015 ... ... encourages people across the United States to support their local poison centers through ... been designated as #GivingTuesday: calls it “a day that inspires people to ...
(Date:11/24/2015)... Marne, MI (PRWEB) , ... November 24, 2015 , ... ... has released a series of recent video interviews with some of the staff members ... life at the residential treatment facility, as well as some of the things that ...
(Date:11/24/2015)... ... ... Aided by seed funding from the Ron Foley Foundation, researchers at Western ... how to detect and treat pancreatic cancer (PC). , WCHN researchers will focus ... (ncRNA), genetic material that is present in the blood of patients with PC. ...
(Date:11/24/2015)... ... November 24, 2015 , ... Abington Hospital – Jefferson ... of Quality® Bariatric Surgery Facility for treating individuals living with morbid or extreme ... services available to its members to help them make informed decisions about their ...
(Date:11/24/2015)... ... November 24, 2015 , ... Dr. Rodney E. Willey , has answered a ... Koala Center for Sleep Disorders, provides treatment for snoring and sleep apnea through ... a Koala Center for Sleep Disorders in the US, one of four in the Illinois ...
Breaking Medicine News(10 mins):
(Date:11/24/2015)... , November 24, 2015 --> ... report "Spine Biologics Market by Product Type (Bone Graft, Bine ... Discectomy and Fusion, Posterior Lumbar Interbody Fusion), End User, and ... global market was valued at $1.90 Billion in 2014 and ... CAGR of 4.4% during the forecast period of 2015 to ...
(Date:11/24/2015)... LAUSANNE and BERN, Switzerland ... SA, the ARTORG Center for Biomedical Engineering Research of ... and the Division of Endocrinology, Diabetes and Clinical Nutrition ... announce the start of an exclusive collaboration to develop ... control algorithm for the personalised delivery of insulin for ...
(Date:11/24/2015)... st  Scientific Assembly and Annual Meeting of the Radiological Society ... Chicago on Nov-29 th through Dec-4 ...  Scientific Assembly and Annual Meeting of the Radiological Society of ... Chicago on Nov-29 th through Dec-4 th , ... present its revolutionary whole body CZT digital SPECT/CT solution at the ...
Breaking Medicine Technology: